About the Company
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis. The company was named Isis Pharmaceuticals until December 2015.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $IONS News
Ionis Pharmaceuticals gets grant for modified oligonucleotide for reducing lrrk2 rna in neurodegenerative diseases
Discover how Ionis Pharmaceuticals' patent for modified oligonucleotides aims to reduce LRRK2 levels and treat Parkinson's disease symptoms effectively.
Ionis Publishes 2023 Corporate Responsibility Report
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today published its 2023 Corporate Responsibility Report: Action for a Healthier Future. The report details Ionis' relentless passion to create better ...
Ionis Pharmaceuticals Inc (IONS) Stock: Evaluating the Annual Growth
Based on Ionis Pharmaceuticals Inc (IONS), the company’s capital structure generated 0.79 points at debt to capital in total, while cash flow to debt ratio is standing at -0.21. The debt to equity ...
The -9.87% Simple Moving Average of Ionis Pharmaceuticals Inc’s (IONS) Stock in the Past 200 Days
During the last 5 trading sessions, IONS fell by -4.73%, which changed the moving average for the period of 200-days by -0.29% in comparison to the 20-day moving average, which settled at $42.87. In ...
Top pharmaceutical company evaluates Optimer for precision liver medicine
The Optimer delivery vehicle was developed to selectively target cells linked to fibrotic liver disease, as part of a fee-for-service partnership with the pharmaceutical company that began in 2020.
Oligonucleotide Synthesis Market Worth $19.7 billion | MarketsandMarkets™
Oligonucleotide Synthesis Market in terms of revenue was estimated to be worth $8.8 billion in 2024 and is poised to reach ...
MoneyTalks: Brokers see risk, rewards and resilience in two health care stocks
MoneyTalks is Stockhead’s regular recap of the ASX stocks, sectors and trends that fund managers and analysts are looking at ...
Ionis to hold first quarter 2024 financial results webcast
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Tuesday, May 7th at 11:30 a.m. Eastern Time to discuss its first quarter 2024 financial results.
Rx Rundown: Vertex Pharmaceuticals, Bristol Myers Squibb, Novartis and more
Vertex Pharmaceuticals announced its biggest M&A play yet, acquiring Alpine Immune Sciences for $4.9 billion. MM+M is proud ...
News - Neurocrine Biosciences
Neurocrine Biosciences has announced that the complete study results from its Phase III KINECT-HD study of valbenazine in chorea associated with Huntington's disease (HD) has been published in The ...
Hepion ends Phase 2 study for NASH drug due to cash restraints
Hepion Pharmaceuticals (HEPA) has decided to wind down its ASCEND-NASH Phase 2 study due to cash constraints as it explores ...
Oligonucleotide Synthesis Market Worth $19.7 billion | MarketsandMarkets
Oligonucleotide Synthesis Market in terms of revenue was estimated to be worth $8.8 billion in 2024 and is poised to reach ...
Loading the latest forecasts...